Neurology and Therapy最新文献

{"title":"Comparative Efficacy of Zilucoplan Versus Intravenous Immunoglobulin, Eculizumab, and Ravulizumab Using Matching-Adjusted Indirect Comparisons.","authors":"April Betts, Saiju Jacob, Abhiroop Chakravarty, Jitender Takyar, Arju Dhawan, Carolina Barnett Tapia, Vikalp Maheshwari","doi":"10.1007/s40120-026-01021-y","DOIUrl":"https://doi.org/10.1007/s40120-026-01021-y","url":null,"abstract":"<p><strong>Introduction: </strong>Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder which impacts signaling at the neuromuscular junction. While new targeted therapies have emerged, there is no direct comparative evidence. This study aimed to compare the efficacy of zilucoplan with eculizumab, intravenous immunoglobulin (IVIg), and ravulizumab using matching-adjusted indirect comparisons (MAICs).</p><p><strong>Methods: </strong>Phase 3 studies of complement component 5 (C5) inhibitors and IVIg were identified through a literature review. MAICs were conducted for zilucoplan versus IVIg, zilucoplan versus ravulizumab (both comparisons in patients with gMG), and zilucoplan versus eculizumab (in patients with refractory gMG). Propensity score-based weighting methods were used to balance covariates between trial populations. Continuous outcomes were analyzed through linear regression, and dichotomous outcomes were analyzed through logistic regression. Treatment effects were presented as mean differences or odds ratios (ORs) with 95% confidence intervals (CIs). Scenario analyses were performed.</p><p><strong>Results: </strong>Compared with IVIg, zilucoplan was associated with statistically significant improvements in the Quantitative Myasthenia Gravis score (QMG) at 2 weeks (OR: - 1.95; 95% CI: - 3.50, - 0.39) and 4 weeks (OR: - 3.30; 95% CI: - 4.89, - 1.71). Compared with eculizumab at 24/26 weeks, the MAIC analysis showed statistically significant differences favoring zilucoplan for the MG Activities of Daily Living (MG-ADL) score (OR: - 1.99; 95% CI: - 3.30, - 0.69), the Quantitative Myasthenia Gravis (QMG) score (OR: - 3.23; 95% CI: - 4.63, - 1.82), and the Myasthenia Gravis Composite questionnaire (MGC) (OR: - 4.27; 95% CI: - 6.79, - 1.76) in patients with refractory gMG. Compared with ravulizumab at 24/26 weeks, the MAIC analysis showed statistically significant differences favoring zilucoplan for the MG-ADL (OR: - 2.70; 95% CI: - 3.74, - 1.67), QMG (OR: - 5.72; 95% CI: - 7.02, - 4.43), and the Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL-15r) (OR: - 5.51; 95% CI - 7.63, - 3.38) scores.</p><p><strong>Conclusions: </strong>In this analysis, zilucoplan was associated with a significantly higher magnitude of clinically meaningful improvement in QMG and MG-ADL scores compared to IVIg and two C5 inhibitors, eculizumab and ravulizumab. In the absence of head-to-head clinical data, these findings provide additional evidence to assist with treatment decisions in this setting.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Neurologists in the Management of Uncontrolled Epilepsy in Spain: Opportunities for Optimization.","authors":"David García-Azorín, Luis Lobato, Javier Riancho, Juan J Poza, Ángel Aledo-Serrano","doi":"10.1007/s40120-026-01039-2","DOIUrl":"https://doi.org/10.1007/s40120-026-01039-2","url":null,"abstract":"<p><p>Epilepsy is a major societal burden with a significant impact on patients' health and quality of life. The primary goal in epilepsy management is to achieve freedom from all types of seizures. Early treatment with antiseizure medications plays a crucial role in this regard, preventing seizure recurrence, limiting disease progression and comorbidities, and improving both prognosis and quality of life. However, initial treatment is typically managed by non-epilepsy specialists, and there are considerable gaps in care that need to be addressed. In order to support non-epilepsy experts in the initial management of uncontrolled epilepsy, we report here on the most significant challenges and obstacles encountered by non-epilepsy specialists in their daily clinical routine, based on literature evidence and outcomes from our recent survey of Spanish neurologists, and provide recommendations to improve patient care.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149025626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Spain, Greece, and Portugal.","authors":"Raquel Yahyaoui, Argirios Dinopoulos, Francina Munell, José Pedro Vieira, Manuela A Santos, David Gómez-Andrés, Grace McCarthy, Matthias Bischof, Michel A Kroes, Dimitrios I Zafeiriou","doi":"10.1007/s40120-026-01032-9","DOIUrl":"https://doi.org/10.1007/s40120-026-01032-9","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with spinal muscular atrophy (SMA) may receive early treatment, ideally before symptoms present, if diagnosed through newborn screening (NBS). We aimed to evaluate the cost-effectiveness of including SMA in NBS programs in Spain, Greece, and Portugal.</p><p><strong>Methods: </strong>A cost-utility model, incorporating both a decision tree and Markov model, compared costs and health outcomes between two scenarios: including SMA in the NBS program with subsequent treatment compared with no NBS and treatment at symptom onset. A base-case analysis was conducted based on payers' perspective over a lifetime time horizon, with an annual discount rate of 3% for Spain, 3.5% for Greece, and 4% for Portugal applied to both costs and health effects. Model inputs were based on existing literature, local data, and expert panel opinion. Deterministic, probabilistic, and scenario sensitivity analyses were conducted to assess model robustness.</p><p><strong>Results: </strong>Including SMA in NBS programs for Spain, Greece, and Portugal would allow early identification and treatment initiation for 97% (n = 33), 89% (n = 8), and 86% (n = 6) of patients per year in Spain, Greece, and Portugal, respectively. In the base-case analysis (lifetime time horizon), NBS for SMA resulted in significant cost savings for Spain (€32,327,624), Greece (€1,778,695), and Portugal (€4,333,014) compared with a scenario with no NBS. NBS for SMA resulted in a total of 837, 199, and 135 quality-adjusted life-years (QALYs) compared with 433, 131, and 89 QALYs without NBS, leading to a gain of 404, 68, and 46 QALYs in Spain, Greece, and Portugal, respectively. Sensitivity analyses were consistent with base-case outcomes, demonstrating the robustness of base-case findings.</p><p><strong>Conclusion: </strong>In Spain, Greece, and Portugal, implementation of NBS for early identification and treatment of patients with SMA is a cost-effective strategy for improving health outcomes and reducing total costs versus clinical diagnosis and later treatment of patients at symptom onset.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benzodiazepines in Epilepsy: A US Perspective on Clinical Use, Pharmacology, Abuse Methods, and Public Health Considerations.","authors":"Enrique Carrazana, Joseph Sirven, John Stern, Barry Gidal, Andres M Kanner, Adrian L Rabinowicz","doi":"10.1007/s40120-026-01007-w","DOIUrl":"https://doi.org/10.1007/s40120-026-01007-w","url":null,"abstract":"<p><p>Benzodiazepines (BZDs) are indicated for a range of therapeutic conditions and can improve patient outcomes when used appropriately. The role of BZDs in epilepsy management is essential in that they have long been first-line agents for acute seizure cessation, most notably including status epilepticus, with each BZD offering a unique pharmacokinetic profile. BZDs are commonly used to treat seizures because of their rapid onset, pronounced safety and tolerability profiles, and versatility of dosage forms and available routes of administration. Despite their clinical utility in a variety of therapeutic areas for a wide range of conditions, the potential for BZD misuse and abuse remains a topic of public health concern. Particularly in combination with other central nervous system depressants (e.g., opioids, gabapentin, and alcohol), misuse and abuse of BZDs are linked to serious and potentially fatal complications. As such, the US Food and Drug Administration has issued a boxed warning regarding concurrent use of BZDs and opioids, emphasizing the dangers of co-prescribing. Policies and prescribing safeguards are implemented to regulate and promote safe use of BZDs; however, such measures may unintentionally worsen patient care by limiting access for individuals that benefit from therapy for seizure control. The objective of this paper is to identify a practical balance between ensuring access to these essential medications for those who experience clinical benefit while also supporting safe prescribing of BZDs to minimize misuse and abuse. Findings from the present review support continued research, drug utilization policies, and patient education.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Autonomic and Cognitive Functions in Patients with Essential Tremor.","authors":"Eda Özsezen, Nevin Pazarci","doi":"10.1007/s40120-026-01035-6","DOIUrl":"https://doi.org/10.1007/s40120-026-01035-6","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate autonomic and cognitive functions in patients with essential tremor (ET) and investigate their correlation.</p><p><strong>Methods: </strong>A total of 38 patients with ET and 35 healthy volunteers were included in the study. Electrophysiological assessment of the autonomic nervous system was performed using the sympathetic skin response (SSR) and RR interval variation analyses. Additionally, cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) for all participants.</p><p><strong>Results: </strong>In the patient group, compared with the control group, median and tibial nerve SSR latencies were greater, and amplitudes were lower in both the upper and lower extremities. SSR latencies were prolonged in several upper- and lower-extremity recordings, and the right tibial SSR amplitude was significantly reduced (p < 0.05); the remaining amplitude differences showed a similar trend without reaching statistical significance. Although RR interval variation was lower in patients than in controls during both rest and deep breathing, no statistically significant difference was detected. MoCA scores were significantly lower in patients than in healthy volunteers. Subgroup analysis revealed that this difference was particularly prominent in visual-spatial/executive functions and language function. No correlation was detected between the SSR, RR interval variation, or MoCA in either the patient or control group.</p><p><strong>Conclusion: </strong>Patients with ET demonstrated electrophysiological findings suggestive of altered sympathetic autonomic function, together with lower cognitive performance. However, parasympathetic dysfunction was not demonstrated by analysis of RR interval variation.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Preferences of Physicians of Pediatric Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment.","authors":"Jeff Schein, Marjolaine Gauthier-Loiselle, Yan Meng, Maryaline Catillon, Beatrice Libchaber, Francesca Lee, Martin Cloutier, Ann Childress","doi":"10.1007/s40120-026-01033-8","DOIUrl":"https://doi.org/10.1007/s40120-026-01033-8","url":null,"abstract":"<p><strong>Introduction: </strong>Evidence on how treatment attributes, especially adverse events, influence preferences of physicians treating pediatric patients with attention-deficit/hyperactivity disorder (ADHD) is scant. This discrete choice experiment aimed to address this evidence gap.</p><p><strong>Methods: </strong>A web-based survey was completed by physicians treating pediatric patients with ADHD in the United States (US) and Canada recruited from a market research firm's panel (12/2024-01/2025). Treatment attributes evaluated included efficacy (improvement in ADHD symptoms) and safety (irritability, upper abdominal pain, insomnia, somnolence, decreased appetite, vomiting), identified from clinical inputs and published data. Physicians' preferences and willingness to trade-off were estimated using conditional logistic regression. Attributes' relative importance was assessed. Subgroups were stratified by physician subspecialty and by patients' age group.</p><p><strong>Results: </strong>The sample included 404 physicians in the US and 402 in Canada (50.2% and 49.8% psychiatrists, respectively). US physicians were on average willing to trade 0.42, 0.36, 0.34, 0.32, and 0.22 percentage points of improvement in ADHD symptoms to achieve a 1-percentage-point reduction in the risk of irritability, upper abdominal pain, insomnia, somnolence, and decreased appetite, respectively, with similar ranges for Canadian physicians (0.22-0.38). In the US, the relative importance of efficacy and that of all safety-related attributes assessed was both 50.0%, whereas, in Canada, this was 53.7% and 46.3%, respectively. In both countries, the most important safety-related attributes were the risks of insomnia (US: 14.5%; Canada: 12.5%), somnolence (US: 13.7%; Canada: 11.0%), and decreased appetite (US: 10.6%; Canada: 11.4%). Psychiatrists placed greater relative importance on efficacy compared to primary care physicians/pediatricians. Findings were consistent when physicians considered treating children and adolescents.</p><p><strong>Conclusion: </strong>US and Canadian physicians valued efficacy and safety similarly when considering pediatric ADHD treatments, with some differences by subspecialty. Understanding drivers of physician preferences and how they may diverge from that of parents/caregivers may facilitate informed discussions and effective shared decision-making.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on Parkinson's Disease Psychosis: Epidemiology, Mechanisms and Management.","authors":"Caroline Kruse, Daniel Weintraub, John Duda, James F Morley","doi":"10.1007/s40120-026-01014-x","DOIUrl":"https://doi.org/10.1007/s40120-026-01014-x","url":null,"abstract":"<p><p>Psychosis in Parkinson's disease (PD) is a common and debilitating non-motor symptom that can occur at any stage of the disease. PD psychosis (PDP) manifests as a diverse clinical spectrum that can include misperceptions, passage and presence phenomena, hallucinations, and delusions, alone or in combination. This review explores the epidemiology and underlying neurobiological mechanisms of psychosis in PD, describes the symptom spectrum experienced by patients, and reviews the evidence supporting current and future therapies for psychosis in PD. Pimavanserin and clozapine are the only pharmacologic therapies for PDP that have been found to be efficacious in randomized controlled trials, though quetiapine is most frequently used despite lacking positive trial results. Future research that continues to clarify the exact pathophysiology of psychosis in PD will improve the current therapeutic approaches, and ongoing randomized clinical trials of these therapies are necessary to identify the safest and most efficacious treatments for PD patients with psychosis.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148920389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Rimegepant for the Acute Treatment of Migraine Among Participants Using Different Types of Preventive Therapy: Analyses from CONFIDENCE.","authors":"Richard B Lipton, Peter J Goadsby, Patricia Pozo-Rosich, Alexandre Urani, Giorgio Lambru, Todd J Schwedt, Kristina M Fanning, Ryan C Bostic, Feng Dai, Lucy Abraham, Karin Hygge Blakeman","doi":"10.1007/s40120-026-01024-9","DOIUrl":"https://doi.org/10.1007/s40120-026-01024-9","url":null,"abstract":"<p><strong>Introduction: </strong>This analysis assessed the real-world effectiveness of rimegepant for the acute treatment of migraine in patients taking different types of preventive medication.</p><p><strong>Methods: </strong>The prospective, observational, CONFIDENCE study recruited participants in the United States with 3-14 headache days/30 days and a rimegepant prescription for the acute treatment of migraine via the Migraine Buddy^® app. Over a 28-day period, participants reported daily on the occurrence, treatment, and outcomes of migraine attacks. The proportion of rimegepant-treated attacks that achieved meaningful pain relief, meaningful improvement in function, or treatment satisfaction were calculated by preventive medication type [none; oral preventive medication (OPM) only; onabotulinumtoxinA (onaBoNT-A) with/without OPM; or calcitonin gene-related peptide monoclonal antibody (CGRP mAb) with/without OPM]. Pain and functional outcomes were compared between attacks treated with rimegepant versus other acute medication combinations using adjusted generalized linear mixed models with logit link and random intercept for each participant.</p><p><strong>Results: </strong>Among 2169 rimegepant-treated attacks, meaningful pain relief was achieved at 2 h and 4 h in 61.3% and 81.8%, respectively; corresponding values for meaningful improvement in function were 57.6% and 78.5%. Odds for all outcomes were higher with rimegepant versus other acute medication treatment combinations. Satisfaction with rimegepant treatment of the attack was > 60% across domains related to speed and effectiveness. Rates and adjusted odds ratios [aORs (95% CI)] for meaningful pain relief within 2 h with rimegepant versus other acute medication treatment combinations were: all attacks 61.3% versus 49.6%, aOR = 1.93 (1.52, 2.45), P < 0.001; no preventive medication 70.0% versus 41.8%, aOR = 4.56 (2.09, 9.92), P < 0.001; OPM 64.7% versus 56.5%, aOR = 1.76 (1.06, 2.90), P < 0.05; onaBoNT-A 62.0% versus 49.5%, aOR = 1.89 (1.24, 2.87), P < 0.01; and CGRP mAb 54.4% versus 46.8%, aOR = 1.66 (1.09, 2.53), P < 0.05.</p><p><strong>Conclusion: </strong>High rates of meaningful pain relief, meaningful improvement in function, and treatment satisfaction were observed with rimegepant for the acute treatment of migraine when used alongside different types of preventive medication in the real world.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT06467370. Graphical abstract available for this article.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148920380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cenobamate Improves Emotional Dysregulation, Impulsivity, and Apathy in Drug-Resistant Focal Epilepsy: A Longitudinal Neuropsychological Study.","authors":"Ilaria Sammarra, Adriana Saraceno, Iolanda Martino, Alessia Vono, Francesca Felicia Operto, Francesco Fortunato, Antonio Gambardella","doi":"10.1007/s40120-026-01022-x","DOIUrl":"https://doi.org/10.1007/s40120-026-01022-x","url":null,"abstract":"<p><strong>Introduction: </strong>Although effects on cognitive function have been reported during cenobamate (CNB) treatment, far less is known about how it may affect neuropsychological domains such as apathy, emotion dysregulation, and impulsivity. This prospective longitudinal study aims to assess psychopathological and cognitive changes after CNB introduction in adults with drug-resistant focal epilepsy, accounting for seizure outcome and burden of concomitant anti-seizure medication (ASM).</p><p><strong>Methods: </strong>We consecutively recruited adults with drug-resistant focal epilepsy who had undergone a comprehensive neuropsychological evaluation at baseline, before starting CNB, and at follow-up, 12 months after treatment introduction. The psychopathological battery included Beck Depression Inventory-II (BDI-II), State-Trait Anxiety Inventory, Difficulties in Emotion Regulation Scale (DERS-36), Barratt Impulsiveness Scale (BIS-11), Apathy Evaluation Scale (AES), and Quality of Life in Epilepsy Inventory (QoLIE-31). The cognitive assessment comprised Rey Auditory Verbal Learning Test (RAVLT), Digit-Span, Rey-Osterrieth Complex Figure Test, WEIGL, FAS, Stroop Color and Word Test, and Symbol Digit Modalities Test (SDMT). We applied linear mixed-effects models adjusted for responder status and total concomitant ASM defined daily dose (DDD) ratio.</p><p><strong>Results: </strong>Our cohort included 27 individuals (16 female; mean age 42.4 ± 16.7 years) showing a 74% responder rate with 30% achieved seizure freedom at follow-up. CNB treatment was associated with favorable changes in BDI-II (q = 0.009), DERS-36 (q = 2.36 × 10^-5), BIS-11 (q = 6.30 × 10^-8), AES (q = 4.87 × 10^-5), and QoLIE-31 (q = 0.009). RAVLT-Immediate performance likewise improved (q = 0.004), whereas SDMT worsened over time (q = 0.002); the remaining domains were unchanged. These effects remained significant after adjustment for responder status and total concomitant ASM DDD ratio: BDI-II [β (95% CI) = - 0.582 (- 0.943, - 0.221)], DERS-36 [β (95% CI) = - 0.550 (- 0.739, - 0.361)], BIS-11 [β (95% CI) = - 0.932 (- 1.144, - 0.719)], AES [β (95% CI) = - 1.001 (- 1.330, - 0.673)], QoLIE-31 [β (95% CI) = 0.488 (0.185, 0.791)], RAVLT-Immediate performance [β (95% CI) = 0.446 (0.255, 0.636)], and SDMT [β (95% CI) = - 0.294 (- 0.425, - 0.163)].</p><p><strong>Conclusion: </strong>Adjunctive CNB was correlated with psychopathological improvements alongside domain-specific cognitive changes, independent of seizure outcome and concomitant ASM burden. These findings further expand current knowledge on CNB impact and tolerability profile.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple Sclerosis.","authors":"Clair-Antoine Veyrier, Patrick Vermersch, Olivier Casez, Olivier Heinzlef, Marianne Payet, Laura Luciani, Nicolas Collongues, Martin Duracinsky","doi":"10.1007/s40120-026-00959-3","DOIUrl":"10.1007/s40120-026-00959-3","url":null,"abstract":"<p><strong>Introduction: </strong>Relapsing-remitting multiple sclerosis (RRMS) requires prolonged use of disease-modifying therapies (DMTs), often perceived as burdensome. This study explored the lived treatment experiences of long-term DMT users with RRMS.</p><p><strong>Methods: </strong>This qualitative, non-interventional study used semi-structured interviews with 20 French-speaking adults with RRMS treated with DMTs for ≥ 10 years. Participants were recruited in France via patient associations and neurology clinics. Exclusion criteria included progressive MS or cognitive impairment. Interviews were conducted remotely and transcribed for thematic analysis using NVivo software, guided by a general inductive and grounded theory framework. Data saturation was monitored, and coding was performed by multiple researchers to ensure reliability.</p><p><strong>Results: </strong>Participants (mean age 52 years; 60% female; mean disease duration 20 years) reported strong preference for oral or infrequent infusion DMTs due to lower perceived treatment burden. Frequent home injections were linked with anxiety and reduced autonomy. Voluntary treatment pauses were common, motivated by fatigue or social needs, but constrained by the fear of relapse. Treatment experiences influenced identity and required substantial daily organization.</p><p><strong>Conclusion: </strong>Long-term patients with RRMS incorporate DMTs into their routines and identities, favoring less frequent, lower-burden regimens. Findings support the need for personalized care strategies that consider treatment fatigue and promote shared decision-making.</p>","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"1917-1929"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}